Hydrochloric Acid

Hydrochloric Acid

SCHEMBL507871

Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12.Cl.Cl

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 known ✓ O75116 13/20 0.98
ROCK1 known ✓ Q13464 12/20 0.98
PRKCD known ✓ Q05655 5/20 0.98
PRKD3 known ✓ O94806 4/20 0.98
PRKCZ known ✓ Q05513 4/20 0.98
LCK known ✓ P06239 1/20 0.98
FGFR1 known ✓ P11362 1/20 0.98
FLT4 known ✓ P35916 1/20 0.98
KDR known ✓ P35968 1/20 0.98
PRKCG known ✓ P05129 3/20 0.61
PRKCB known ✓ P05771 3/20 0.61
PRKCA known ✓ P17252 3/20 0.61
PRKCH known ✓ P24723 3/20 0.61
PRKCI known ✓ P41743 3/20 0.61
PRKCE known ✓ Q02156 3/20 0.61
PRKCQ known ✓ Q04759 3/20 0.61
PRKD1 known ✓ Q15139 3/20 0.61
HTR1A known ✓ P08908 1/20 0.42
ADRA2A known ✓ P08913 1/20 0.42
ADRA2B known ✓ P18089 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2460111 1.00 ROCK2 (0.98) ROCK2ROCK1PRKACAPRKCDPRKD3
Hydrochloric Acid SCHEMBL29396389 1.00 ROCK2 (0.98) ROCK2ROCK1PRKACAPRKCDPRKD3
Hydrochloric Acid SCHEMBL29781011 1.00 ROCK2 (0.98) ROCK2ROCK1PRKACAPRKCDPRKD3
Hydrochloric Acid SCHEMBL2461354 1.00 ROCK2 (0.98) ROCK2ROCK1PRKACAPRKCDPRKD3
Hydrochloric Acid SCHEMBL2456059 1.00 ROCK2 (0.98) ROCK2ROCK1PRKACAPRKCDPRKD3
Hydrochloric Acid SCHEMBL507872 1.00 ROCK2 (0.98) ROCK2ROCK1PRKACAPRKCDPRKD3
Hydrochloric Acid SCHEMBL30009735 1.00 ROCK2 (0.98) ROCK2ROCK1PRKACAPRKCDPRKD3
SCHEMBL29372951 0.99 ROCK2 (1.00) ROCK2ROCK1PRKACAPRKCDPRKD3
SCHEMBL30069136 0.99 ROCK2 (1.00) ROCK2ROCK1PRKACAPRKCDPRKD3
SCHEMBL124161 0.99 ROCK2 (1.00) ROCK2ROCK1PRKACAPRKCDPRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4728051-A1 STANDARDISING PLURIPOTENT STEM CELLS United Kingdom Research and Innovation (GB) 2026-04-22 EP claimed
EP-4709477-A2 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES The Texas A&M University System (US) 2026-03-18 EP claimed
EP-4615506-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES Sahin, Fikret (TR) 2025-09-17 EP claimed
US-20250206845-A1 PHARMACEUTICAL COMPOSITION INCLUDING RHO-KINASE INHIBITOR FOR PREVENTION OR TREATMENT OF CUTANEOUS FIBROTIC DISORDERS SUCH AS KELOID, ETC. AND USE THEREOF SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-06-26 US claimed
WO-2025088022-A1 METHOD FOR GENERATING HOMOGENOUS, SIZE-DEFINED PSEUDO-ISLETS OF PORCINE ORIGIN BY RHO/ROCK PATHWAY INHIBITION Technische Universität Dresden, Körperschaft des öffentlichen Rechts (DE) 2025-05-01 WO claimed
WO-2024258363-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES SAHIN FIKRET (TR) 2024-12-19 WO claimed
WO-2024256607-A1 STANDARDISING PLURIPOTENT STEM CELLS UNITED KINGDOM RESEARCH AND INNOVATION (GB) 2024-12-19 WO claimed
WO-2024238454-A2 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES THE TEXAS A&M UNIVERSITY SYSTEM (US) 2024-11-21 WO claimed
CN-117305233-B Exosome of bone marrow mesenchymal stem cells, in vitro culture method and application 北科芯(北京)干细胞医学研究院有限公司 2024-07-05 CN claimed
CN-117402819-B Exosome of bone marrow mesenchymal stem cells, in vitro culture method and application 天津科融中健生物科技有限责任公司 2024-06-14 CN claimed
WO-2015200920-A1 CULTURED MAMMALIAN LIMBAL STEM CELLS, METHODS FOR GENERATING THE SAME, AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-12-30 WO claimed
US-9006394-B2 Peptide-presenting surfaces for long-term culture of pluripotent cells WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2015-04-14 US claimed
US-20140287505-A1 PEPTIDE-PRESENTING SURFACES FOR LONG-TERM CULTURE OF PLURIPOTENT CELLS WISCONSIN ALUMNI RESEARCH FOUNDATION 2014-09-25 US claimed
EP-2718422-A2 CULTURE MEDIA FOR STEM CELLS Koninklijke Nederlandse Akademie van Wetenschappen (KNAW) (NL) 2014-04-16 EP claimed
US-8648170-B2 Peptide-presenting surfaces for long-term culture of pluripotent cells WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2014-02-11 US claimed
WO-2012168930-A2 Culture media for stem cells KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (KNAW) (NL) 2012-12-13 WO claimed
US-20120010196-A1 METHODS OF TREATING NEURODEGENERATIVE DISORDERS AND DISEASES WESTERN UNIVERSITY OF HEALTH SCIENCES 2012-01-12 US claimed
US-20110223177-A1 TREATMENT OF FIBROTIC EYE DISORDERS UNIVERSITY OF EAST ANGLIA (GB) 2011-09-15 US claimed
EP-2323637-A1 TREATMENT OF FIBROTIC EYE DISORDERS University of East Anglia (GB) 2011-05-25 EP claimed
WO-2010029350-A1 TREATMENT OF FIBROTIC EYE DISORDERS UNIVERSITY OF EAST ANGLIA (GB) 2010-03-18 WO claimed